Center-Involved Diabetic Macular Edema Persisting Despite Anti-VEGF Therapy
Clinical Scenario
Center-involved diabetic macular edema (CI-DME) represents the highest-risk subtype of DME because edema directly involves the central macula. CI-DME is classified separately from non-center-involved DME given this distinction's direct impact on treatment selection and the risk of visual loss.
Previous Treatment Line — Goals Not Achieved
First-line intravitreal anti-VEGF therapy for CI-DME — with agents including aflibercept, ranibizumab, or bevacizumab — has been administered but has not achieved the targeted outcomes: improvement in vision and central macular thickness, achievement of 20/20 visual acuity, and resolution of macular edema. Macular edema involving the center of the macula persists.
Next-Step Approach
For CI-DME that persists following anti-VEGF therapy, a surgical laser-based intervention targeting the macular area is the evidence-supported next step. The complete protocol — including the specific technique, operative parameters, and patient-selection criteria — is available in the full regimen.
Target outcome: Resolution of persistent macular edema.
References
- Diabetic macular edema should be classified as either center-involved (CI-DME) or non-center-involved DME (NCI-DME).
- Because the risk of visual loss is greatest if macular edema is at the center of the macula, DME is now subdivided as either CI-DME or NCI-DME.
- Based on these studies, anti-VEGF therapy is the initial treatment choice for CI-DME, with possible subsequent focal laser surgery treatment for persistent edema.
- A modified ETDRS laser surgery treatment is currently recommended; it includes a less intense laser energy, has greater spacing than for a grid, directly targets microaneurysms, and avoids foveal vasculature within at least 500 µm of the center of the macula.
View source ↗